The lausanne institutional biobank: A new resource to catalyse research in personalised medicine and pharmaceutical sciences

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Mooser, Vincent ^a   Currat, Christine ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Biobank; Biomarkers; Drug discovery and development; Genomics; Personalised medicine

Indexed keywords

BIOBANK; BIOMICS; CLINICAL RESEARCH; EXPOSOMICS; GENOMICS; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; METABOLOMICS; PERSONALIZED MEDICINE; PHARMACEUTICS; POPULATION; REVIEW; TRANSCRIPTOMICS; DRUG DEVELOPMENT; HEALTH CARE FACILITY; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA; SWITZERLAND;

BIOLOGICAL MARKER; TRANSCRIPTOME;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; SWITZERLAND; TRANSCRIPTOME;

EID: 84928970051     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.14033     Document Type: Review

References (26)

1. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Human Genet. 2012;90(1):7-24.
2. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64-9.
3. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, et al. An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People. Science. 2012.
4. Coventry A, Bull-Otterson LM, Liu X, Clark AG, Maxwell TJ, Crosby J, et al. Deep resequencing reveals excess rare recent variants consistent with explosive population growth. Nat Commun. 2010;1(131.
5. Bamshad MJ, Shendure JA, Valle D, Hamosh A, Lupski JR, Gibbs RA, et al. The Centers for Mendelian Genomics: a new large-scale initiative to identify the genes underlying rare Mendelian conditions. Am J Med Genet Part A. 2012;158A(7):1523-5.
6. Ginsburg G. Medical genomics: Gather and use genetic data in health care. Nature. 2014;508(7497):451-3.
7. Mooser V. Genomics and personalized medicine. Praxis. 2014;103(10):567-71.
8. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013;31(12):1102-10.
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29-40.
10. Ziegler A, Koch A, Krockenberger K, Grosshennig A. Personalized medicine using DNA biomarkers: a review. Hum Genet. 2012;131(10):1627-38.
11. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161-5.
12. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, Mangino M, et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet. 2008;40(5):575-83.
13. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Ran-domized Trial. JAMA: the journal of the American Medical Association. 2012:1-10.
14. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New biotechnology. 2012;29(6):613-24.
15. Elliott P, Peakman TC, Biobank UK. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37(2):234-44.
16. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.
17. Maillard PY. Sequencing the human genome and society. Praxis. 2014;103(10):551-3.
18. Barazzetti G, Kaufmann A, and Benaroyo L. Ethical and social issues associated with genomic medicine. Praxis. 2014;103(10):573-7.
19. Raisaro JL, Ayday E, Hubaux JP. Patient privacy in the genomic era. Praxis. 2014;103(10):579-86.
20. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-13.
21. Windhager S, Schaschl H, Schaefer K, Mitteroecker P, Huber S, Wallner B, Fieder M. Variation at genes influencing facial morphology are not associated with developmental imprecision in human faces. PLoS One. 2014;9(6):e99009.
22. The TG, Hdl Working Group of the Exome Sequencing Project NHL, Blood I. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 2014;371(1):22-31.
23. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. N Engl J Med. 2014;371(1):32-41.
24. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981;305(9):478-82.
25. Hu Y, Li L, Ehm MG, Bing N, Song K, Nelson MR, Talmud PJ, et al. The benefits of using genetic information to design prevention trials. Am J Hum Genet. 2013;92(4):547-57.
26. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466-70.